Literature DB >> 20189815

Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.

Mingzhang Gao1, Min Wang1, Kathy D Miller2, Gary D Hutchins1, Qi-Huang Zheng1.   

Abstract

Cannabinoids have been recently proposed as a new family of potential antitumor agents, and cannabinoid receptor 2 (CB2) is believed to be over-expressed in tumor cells. This study was designed to develop new radioligands for imaging of CB2 receptor in cancer using biomedical imaging technique positron emission tomography (PET). Carbon-11-labeled 2-oxoquinoline and 2-chloroquinoline derivatives, [(11)C]6a-d and [(11)C]9a-d, were prepared by O-[(11)C]methylation of their corresponding precursors using [(11)C]CH(3)OTf under basic conditions and isolated by a simplified solid-phase extraction (SPE) method in 40-50% radiochemical yields based on [(11)C]CO(2) and decay corrected to end of bombardment (EOB). The overall synthesis time from EOB was 15-20 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 111-185 GBq/micromol. Radioligand binding assays indicated compounds 6f, 6b, and 9f display potent in vitro binding affinities with nanomolar K(i) values and at least 100-2000-fold selectivity for CB2. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189815     DOI: 10.1016/j.bmc.2010.02.011

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo.

Authors:  Juan R Rodrigues; Jaime Charris; Rosa Ferrer; Neira Gamboa; Jorge Angel; Bianca Nitzsche; Michael Hoepfner; Michael Lein; Klaus Jung; Claudia Abramjuk
Journal:  Invest New Drugs       Date:  2011-07-12       Impact factor: 3.850

2.  Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.

Authors:  Nashaat Turkman; Aleksander Shavrin; Roman A Ivanov; Brian Rabinovich; Andrei Volgin; Juri G Gelovani; Mian M Alauddin
Journal:  Bioorg Med Chem       Date:  2011-08-05       Impact factor: 3.641

3.  Synthesis and preliminary evaluation of [18F]-labeled 2-oxoquinoline derivatives for PET imaging of cannabinoid CB2 receptor.

Authors:  Nashaat Turkman; Aleksander Shavrin; Vincenzo Paolillo; Hsin Hsien Yeh; Leo Flores; Suren Soghomonian; Brian Rabinovich; Andrei Volgin; Juri Gelovani; Mian Alauddin
Journal:  Nucl Med Biol       Date:  2012-01-04       Impact factor: 2.408

4.  In vivo type 2 cannabinoid receptor-targeted tumor optical imaging using a near infrared fluorescent probe.

Authors:  Shaojuan Zhang; Pin Shao; Mingfeng Bai
Journal:  Bioconjug Chem       Date:  2013-10-29       Impact factor: 4.774

5.  Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects.

Authors:  Rawaha Ahmad; Michel Koole; Nele Evens; Kim Serdons; Alfons Verbruggen; Guy Bormans; Koen Van Laere
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

Review 6.  Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system.

Authors:  Ruiqing Ni; Linjing Mu; Simon Ametamey
Journal:  Acta Pharmacol Sin       Date:  2018-06-19       Impact factor: 6.150

7.  Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation.

Authors:  Thomas Rühl; Winnie Deuther-Conrad; Steffen Fischer; Robert Günther; Lothar Hennig; Harald Krautscheid; Peter Brust
Journal:  Org Med Chem Lett       Date:  2012-10-15

8.  Radiofluorination and biological evaluation of N-aryl-oxadiazolyl-propionamides as potential radioligands for PET imaging of cannabinoid CB2 receptors.

Authors:  Rodrigo Teodoro; Rareş-Petru Moldovan; Corinna Lueg; Robert Günther; Cornelius K Donat; Friedrich-Alexander Ludwig; Steffen Fischer; Winnie Deuther-Conrad; Bernhard Wünsch; Peter Brust
Journal:  Org Med Chem Lett       Date:  2013-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.